Alethia Biotherapeutics
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
141 Av Du President-Kennedy Suite SB5100...Phone Number
(514) 858-7666Website
www.alethiabio.comRevenue
$5.4 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Alethia Biotherapeutics
Alethia Biotherapeutics specializes in developing innovative cancer therapies, focusing on the epithelial-to-mesenchymal transition (EMT) to combat chemotherapy resistance and metastatic tumor invasion. Their lead product, AB-16B5, is a clinical stage monoclonal antibody designed to inhibit EMT, showing promising pre-clinical results in enhancing chemotherapy response and reducing cancer cell invasion. The company aims to provide effective treatments for patients with invasive carcinomas. Alethia Biotherapeutics is actively engaged in advancing its research and has received FDA authorization to begin Phase 2 development for AB-16B5.Explore more
Alethia Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alethia Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Alethia Biotherapeutics launches new products
Check out if Alethia Biotherapeutics is spiking on competitors!
Earning: See what the market has to say on Alethia Biotherapeutics recently announced quarterly report
Check if Alethia Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Alethia Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Alethia Biotherapeutics
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Alethia Biotherapeutics has new funding data
Click to see if Alethia Biotherapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Alethia Biotherapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Alethia Biotherapeutics
Compare insights from companies similar to Alethia Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alethia Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alethia Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alethia Biotherapeutics.
Alethia Biotherapeutics financials insights
Gather financial insights about Alethia Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$9.2M
Alethia Biotherapeutics Tech Stack
A closer look at the technologies used by Alethia Biotherapeutics
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Alethia Biotherapeutics
Sign Up For FreeTo access detailed company insights
Alethia Biotherapeutics specializes in developing innovative cancer therapies, focusing on the epithelial-to-mesenchymal transition (EMT) to combat chemotherapy resistance and metastatic tumor invasion. Their lead product, AB-16B5, is a clinical stage monoclonal antibody designed to inhibit EMT, showing promising pre-clinical results in enhancing c... Read More
